Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of ES002023 in Patients With Locally Advanced or Metastatic Solid Tumors
Conditions
Interventions
Part 1 ES002023
Part 2 ES002023
Locations
7
United States
HonorHealth
Scottsdale, Arizona, United States
Fayetteville Oncology
Fayetteville, Arkansas, United States
UCLA
Los Angeles, California, United States
Sarah Cannon Research Institute
Orlando, Florida, United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
NEXT Austin
Austin, Texas, United States
Start Date
December 23, 2021
Primary Completion Date
October 13, 2022
Completion Date
October 13, 2022
Last Updated
May 14, 2025
NCT07177937
NCT07181681
NCT05919264
NCT07387068
NCT06257264
NCT07360314
Lead Sponsor
Elpiscience Biopharma, Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions